UNSPSC 51386300: Nonsteroidal anti inflammatory benzoxazines

Nonsteroidal anti inflammatory drugs made from oxazines (Six-membered heterocycles containing an oxygen and a nitrogen) with a fused benzene ring (benzene is a toxic, volatile hydrocarbon coal distillation byproduct), hence the names BENZ-OXAZINE, BENZ-OXAZINES, or BENZOXAZINES.

UNSPSC 51386300 Nonsteroidal anti-inflammatory benzoxazines is a Class code that in current state and local procurement activity encompasses the purchase of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesalers and direct-to-manufacturer channels to support community health, pharmacy benefit, and emergency response initiatives. State and local buyers soliciting under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The scope of work ranges from discrete commodity purchases of specific pharmaceuticals to broader direct-to-manufacturer pharmacy programs and cooperative contracting frameworks. Issuing bodies include county government (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which extends to participating states including Oregon).

Recent activity centers in Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a response deadline of July 26, 2023—note that this due date appears inconsistent with the posting date and warrants verification. Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, treating the RFI as a preliminary market-intelligence phase before formal solicitation. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with a March 26, 2026 response deadline and July 1, 2026 contract effective date. The MMCAP procurement weights price competitiveness at 75 percent and requires vendors to maintain cGMP and DSCSA compliance, with commercial general liability insurance of $5,000,000 per occurrence.